GLP-1 receptor agonists like semaglutide and liraglutide exert some of their therapeutic effects through interactions with the gut microbiota, affecting metabolic homeostasis, immune responses, and gut barrier function.
Timing-dependent gut flora effectsEach diabetes drug, including GLP-1 agonists, can have conflicting effects on gut bacteria depending on when and how it's administered
What the researchers found
GLP-1 receptor agonists (semaglutide, liraglutide), metformin, SGLT-2 inhibitors (dapagliflozin), and berberine all interact with gut microbiota to exert therapeutic effects in type 2 diabetes. Each drug modulates metabolic homeostasis, immune response, and gut barrier function through microbiome changes. Notably, each drug can have conflicting effects on gut flora depending on timing and mode of administration. The gut microbiota may also impact drug safety profiles, suggesting bidirectional drug-microbiome interactions.
Why it matters
GLP-1 receptor agonists are among the most prescribed medications globally, yet we're still discovering how they work. The gut microbiome connection suggests these peptide drugs have effects beyond direct receptor activation — they reshape the gut ecosystem in ways that contribute to blood sugar control, weight loss, and potentially other benefits. This knowledge could optimize how and when these drugs are prescribed.
How the study worked
Narrative literature review selecting representative glucose-lowering drugs (metformin, dapagliflozin, semaglutide, liraglutide, and berberine) and summarizing evidence for their interactions with gut microbiota in type 2 diabetes treatment.
What this study cannot tell us
This is a narrative review, not a systematic review, so it may not comprehensively cover all relevant studies. Much of the evidence for drug-microbiome interactions comes from animal studies that may not translate to humans. The mechanisms described are largely associative rather than causal. The review combines very different drug classes, making direct comparisons difficult. Individual variation in gut microbiota composition is not adequately addressed.
How to read the evidence
This is a narrative review published in Minerva Endocrinology. It synthesizes existing evidence but does not present new data or use systematic methodology. The underlying evidence is largely preclinical with some human studies.
When this study was published
Published in 2025, this is a current review capturing recent understanding of how the gut microbiome mediates the effects of GLP-1 receptor agonists and other diabetes drugs.
The bigger picture
The gut microbiome is increasingly recognized as a key mediator of drug effects across medicine. For GLP-1 receptor agonists, this adds another layer to their mechanism of action beyond direct hormonal effects. As personalized medicine advances, understanding a patient's gut microbiome could help predict which diabetes drugs will work best for them and guide optimal combination strategies.
Questions still open
- Could pre-treatment gut microbiome profiling predict which patients will respond best to GLP-1 receptor agonists?
- Would combining GLP-1 agonists with probiotics or prebiotics enhance their microbiome-mediated therapeutic effects?
- How do the microbiome effects of GLP-1 agonists differ between diabetic and non-diabetic (obesity-only) patients?
Common questions
How do GLP-1 receptor agonists change gut bacteria?
Does this mean probiotics could make diabetes drugs work better?
Read the original research
Mechanisms of efficacy of drug therapy in type 2 diabetes: the role of microbiomes.
Minerva endocrinology
Citation
Li, Yushan; He, Ziling; Li, Chunyan; Huang, Jing; Yu, Zheng. (2025). Mechanisms of efficacy of drug therapy in type 2 diabetes: the role of microbiomes.. Minerva endocrinology. https://doi.org/10.23736/S2724-6507.25.04306-4